Barbara Bottazzi

Dr. Barbara Bottazzi

orcid

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 1992 in Immunology Today
Verified
Journal Article
Closed access
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
BBBarbara Bottazzi
Barbara Bottazzi
FCFrancesco Colotta
Francesco Colotta
SSSilvano Sozzani
Silvano Sozzani
LRLuigi Ruco
Luigi Ruco

1 April 2005 in Annual Review of Immunology
Verified
Journal Article
Closed access
CGCecilia Garlanda
Cecilia Garlanda
BBBarbara Bottazzi
Barbara Bottazzi
ABAntonio Bastone
Antonio Bastone
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
▪ Abstract C reactive protein, the first innate immunity receptor identified, and serum amyloid P component are classic short pentraxins produced in the liver. Long pentraxins, including the prototype PTX3, are expressed in a variety of tissues. Some long pentraxins are expressed in the brain and some are involved in neuronal plasticity and degeneration. PTX3 is produced by a variety of cells and tissues, most notably dendritic cells and macrophages, in response to Toll-like receptor (TLR) engagement and inflammatory cytokines. PTX3 acts as a functional ancestor of antibodies, recognizing microbes, activating complement, and facilitating pathogen recognition by phagocytes, hence playing a nonredundant role in resistance against selected pathogens. In addition, PTX3 is essential in female fertility because it acts as a nodal point for the assembly of the cumulus oophorus hyaluronan-rich extracellular matrix. Thus, the prototypic long pentraxin PTX3 is a multifunctional soluble pattern recognition receptor at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility.

1 November 2002 in Nature
Verified
Journal Article
Closed access
PDF file
CGCecilia Garlanda
Cecilia Garlanda
EHEmilio Hirsch
Emilio Hirsch
SBSilvia Bozza
Silvia Bozza
ASAntonietta Salustri
Antonietta Salustri
MAMarika De Acetis
Marika De Acetis
Alberto MantovaniAlberto Mantovani
Alberto Mantovani

1 March 2006 in Blood
Verified
Journal Article
Closed access
PDF file
SBSubhra K. Biswas
Subhra K. Biswas
LGLisa Gangi
Lisa Gangi
SPSaki Paul
Saki Paul
TSTiziana Schioppa
Tiziana Schioppa
ASAlessandra Saccani
Alessandra Saccani
ASAntonio Sica
Antonio Sica
To identify the molecular basis underlying the functions of tumor-associated macrophages (TAMs), we characterized the gene expression profile of TAMs isolated from a murine fibrosarcoma in comparison with peritoneal macrophages (PECs) and myeloid suppressor cells (MSCs), using a cDNA microarray technology. Among the differentially expressed genes, 15 genes relevant to inflammation and immunity were validated by real-time polymerase chain reaction (PCR) and protein production. Resting TAMs showed a characteristic gene expression pattern with higher expression of genes coding for the immunosuppressive cytokine IL-10, phagocytosis-related receptors/molecules (Msr2 and C1q), and inflammatory chemokines (CCL2 and CCL5) as expected, as well as, unexpectedly, IFN-inducible chemokines (CXCL9, CXCL10, CXCL16). Immunohistology confirmed and extended the in vitro analysis by showing that TAMs express M2-associated molecules (eg, IL-10 and MGL1), as well as CCL2, CCL5, CXCL9, CXCL10, and CXCL16, but no appreciable NOS2. Lipopolysaccharide (LPS)-mediated activation of TAMs resulted in defective expression of several proinflammatory cytokines (eg, IL-1β, IL-6, TNF-α) and chemokines (eg, CCL3), as opposed to a strong up-regulation of immunosuppressive cytokines (IL-10, TGFβ) and IFN-inducible chemokines (CCL5, CXCL9, CXCL10, CXCL16). Thus, profiling of TAMs from a murine sarcoma revealed unexpected expression of IFN-inducible chemokines, associated with an M2 phenotype (IL-10high, IL-12low), and divergent regulation of the NF-κB versus the IRF-3/STAT1 pathway.

1 March 2010 in Annual Review of Immunology
Verified
Journal Article
Closed access
BBBarbara Bottazzi
Barbara Bottazzi
Andrea DoniAndrea Doni
Andrea Doni
CGCecilia Garlanda
Cecilia Garlanda
Alberto MantovaniAlberto Mantovani
Alberto Mantovani
The innate immune system consists of a cellular and a humoral arm. Pentraxins (e.g., the short pentraxin C reactive protein and the long pentraxin PTX3) are key components of the humoral arm of innate immunity which also includes complement components, collectins, and ficolins. In response to microorganisms and tissue damage, neutrophils, macrophages, and dendritic cells are major sources of fluid-phase pattern-recognition molecules (PRMs) belonging to different molecular classes. Humoral PRMs in turn interact with and regulate cellular effectors. Effector mechanisms of the humoral innate immune system include activation and regulation of the complement cascade; agglutination and neutralization; facilitation of recognition via cellular receptors (opsonization); and regulation of inflammation. Thus, the humoral arm of innate immunity is an integrated system consisting of different molecules and sharing functional outputs with antibodies.

1 December 2006 in Cancer Research
Verified
Journal Article
Closed access
PDF file
ASAlessandra Saccani
Alessandra Saccani
TSTiziana Schioppa
Tiziana Schioppa
Porta ChiaraPorta Chiara
Porta Chiara
SBSubhra K. Biswas
Subhra K. Biswas
MNManuela Nebuloni
Manuela Nebuloni
ASAntonio Sica
Antonio Sica
Tumor-associated macrophages (TAM) are a major inflammatory infiltrate in tumors and a major component of the protumor function of inflammation. TAM in established tumors generally have an M2 phenotype with defective production of interleukin-12 (IL-12) and high IL-10. Here, we report that defective responsiveness of TAM from a murine fibrosarcoma and human ovarian carcinoma to M1 activation signals was associated with a massive nuclear localization of the p50 nuclear factor-κB (NF-κB) inhibitory homodimer. p50 overexpression inhibited IL-12 expression in normal macrophages. TAM isolated from p50−/− mice showed normal production of M1 cytokines, associated with reduced growth of transplanted tumors. Bone marrow chimeras showed that p50 inactivation in hematopoietic cells was sufficient to result in reduced tumor growth. Thus, p50 NF-κB overexpression accounts for the inability of TAM to mount an effective M1 antitumor response capable of inhibiting tumor growth. (Cancer Res 2006; 66(23): 11432-40)